140 related articles for article (PubMed ID: 8225595)
1. Prevention of renal scarring from pyelonephritis in nonhuman primates by vaccination with a synthetic Escherichia coli serotype O8 oligosaccharide-protein conjugate.
Roberts JA; Kaack MB; Baskin G; Svenson SB
Infect Immun; 1993 Dec; 61(12):5214-8. PubMed ID: 8225595
[TBL] [Abstract][Full Text] [Related]
2. Vaccination with a formalin-killed P-fimbriated E. coli whole-cell vaccine prevents renal scarring from pyelonephritis in the non-human primate.
Roberts JA; Kaack MB; Baskin G; Svenson SB
Vaccine; 1995 Jan; 13(1):11-6. PubMed ID: 7762266
[TBL] [Abstract][Full Text] [Related]
3. Immunization against retrograde pyelonephritis. III. Vaccination against chronic pyelonephritis due to Escherichia coli.
Brooks SJ; Lyons JM; Braude AI
J Infect Dis; 1977 Nov; 136(5):633-9. PubMed ID: 335001
[TBL] [Abstract][Full Text] [Related]
4. Maternal immunization with P fimbriae for the prevention of neonatal pyelonephritis.
Kaack MB; Roberts JA; Baskin G; Patterson GM
Infect Immun; 1988 Jan; 56(1):1-6. PubMed ID: 2891616
[TBL] [Abstract][Full Text] [Related]
5. P-fimbriae vaccines. II. Cross reactive protection against pyelonephritis.
Roberts JA; Kaack MB; Baskin G; Korhonen TK; Svenson SB; Winberg J
Pediatr Nephrol; 1989 Oct; 3(4):391-6. PubMed ID: 2577147
[TBL] [Abstract][Full Text] [Related]
6. Prevention of pyelonephritis by immunization with P-fimbriae.
Roberts JA; Hardaway K; Kaack B; Fussell EN; Baskin G
J Urol; 1984 Mar; 131(3):602-7. PubMed ID: 6199527
[TBL] [Abstract][Full Text] [Related]
7. Antibody responses and protection from pyelonephritis following vaccination with purified Escherichia coli PapDG protein.
Roberts JA; Kaack MB; Baskin G; Chapman MR; Hunstad DA; Pinkner JS; Hultgren SJ
J Urol; 2004 Apr; 171(4):1682-5. PubMed ID: 15017266
[TBL] [Abstract][Full Text] [Related]
8. [Effect of immunization with K1-antigen of Escherichia coli on the course of experimental urinary tract infection in the rat].
Straube E; Nimmich W; Broschewitz U; Naumann G
Z Urol Nephrol; 1986 Jun; 79(6):335-46. PubMed ID: 3529745
[TBL] [Abstract][Full Text] [Related]
9. Immunization against retrograde pyelonephritis. II. Prevention of retrograde Escherichia coli pyelonephritis with vaccines.
Brooks SJ; Lyons JM; Braude AI
Am J Pathol; 1974 Feb; 74(2):359-64. PubMed ID: 4590646
[TBL] [Abstract][Full Text] [Related]
10. Lack of protection against ascending Escherichia coli pyelonephritis in diabetic rats following immunization with purified lipopolysaccharide.
Bryan LE; Schollaardt T; Pak CY; Kim CJ; Yoon JW
Can J Microbiol; 1986 Dec; 32(12):967-9. PubMed ID: 3545411
[TBL] [Abstract][Full Text] [Related]
11. Immunoprotection of guinea pigs against experimental acute pyelonephritis after the administration of Escherichia coli purified fimbriae.
Dima VF; Petrovici A; Dima SV; Petrovici M; Burghelea B
Arch Roum Pathol Exp Microbiol; 1989; 48(3):215-25. PubMed ID: 2577515
[TBL] [Abstract][Full Text] [Related]
12. Gal-Gal pili vaccines prevent pyelonephritis by piliated Escherichia coli in a murine model. Single-component Gal-Gal pili vaccines prevent pyelonephritis by homologous and heterologous piliated E. coli strains.
Pecha B; Low D; O'Hanley P
J Clin Invest; 1989 Jun; 83(6):2102-8. PubMed ID: 2566625
[TBL] [Abstract][Full Text] [Related]
13. Alpha-hemolysin contributes to the pathogenicity of piliated digalactoside-binding Escherichia coli in the kidney: efficacy of an alpha-hemolysin vaccine in preventing renal injury in the BALB/c mouse model of pyelonephritis.
O'Hanley P; Lalonde G; Ji G
Infect Immun; 1991 Mar; 59(3):1153-61. PubMed ID: 1671776
[TBL] [Abstract][Full Text] [Related]
14. Preclinical evaluation of group B Neisseria meningitidis and Escherichia coli K92 capsular polysaccharide-protein conjugate vaccines in juvenile rhesus monkeys.
Devi SJ; Zollinger WD; Snoy PJ; Tai JY; Costantini P; Norelli F; Rappuoli R; Frasch CE
Infect Immun; 1997 Mar; 65(3):1045-52. PubMed ID: 9038314
[TBL] [Abstract][Full Text] [Related]
15. Effect of immunization with Escherichia coli K1 antigen on the course of experimental infection of the urinary tract of the rat.
Straube E; Nimmich W; Broschewitz U; Naumann G; Hacker K
Zentralbl Bakteriol Mikrobiol Hyg A; 1987 Jul; 265(3-4):408-19. PubMed ID: 3314264
[TBL] [Abstract][Full Text] [Related]
16. Synthetic peptides corresponding to protective epitopes of Escherichia coli digalactoside-binding pilin prevent infection in a murine pyelonephritis model.
Schmidt MA; O'Hanley P; Lark D; Schoolnik GK
Proc Natl Acad Sci U S A; 1988 Feb; 85(4):1247-51. PubMed ID: 2448796
[TBL] [Abstract][Full Text] [Related]
17. [Effect of immunization with Escherichia coli J5 on the course of experimental pyelonephritis in rats].
Straube E; Naumann G; Broschewitz U
Z Urol Nephrol; 1988 Apr; 81(4):247-55. PubMed ID: 3041706
[TBL] [Abstract][Full Text] [Related]
18. Antigens of Escherichia coli, human immune response, and the pathogenesis of urinary tract infections.
Hanson LA; Ahlstedt S; Fasth A; Jodal U; Kaijser B; Larsson P; Lindberg U; Olling S; Sohl-Akerlund A; Svanborg-Edén C
J Infect Dis; 1977 Aug; 136 Suppl():S144-9. PubMed ID: 330773
[TBL] [Abstract][Full Text] [Related]
19. Protective efficacy and immunogenicity of Escherichia coli K13 diphtheria toxoid conjugate against experimental ascending pyelonephritis.
Kumar V; Ganguly Nk; Joshi K; Mittal R; Harjai K; Chhibber S; Sharma S
Med Microbiol Immunol; 2005 Aug; 194(4):211-7. PubMed ID: 15909203
[TBL] [Abstract][Full Text] [Related]
20. Immunology of pyelonephritis in the primate model: live versus heat-killed bacteria.
Roberts JA; Domingue GJ; Martin LN; Kim JC
Kidney Int; 1981 Feb; 19(2):297-305. PubMed ID: 7014985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
